Related Experiment Video
Updated: May 8, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Prostaglandin E2 alleviates acetaminophen-induced liver injury through DDIT4-enhanced autophagy regulated by
Chao Chen1, Jun Guan1, Shanshan Wu1
1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, China.
Abstract:
Acetaminophen (APAP) overdose is a leading cause of acute liver injury (AILI). While Prostaglandin E2 (PGE2) protects against various forms of acute hepatitis, its underlying mechanisms and the role of circRNA-mediated regulatory networks in AILI remain to be elucidated. AILI was induced in mice by administration of 500 mg/kg APAP, with or without 16,16-dimethyl PGE2 (dmPGE2) pretreatment. Hepatic transcriptomic landscapes (circRNA, miRNA, and mRNA) were characterized by high-throughput sequencing. The circLima1/miR-486/Ddit4 axis was validated using dual-luciferase assays and hepatocyte-specific AAV8-mediated knockdown. Autophagic flux was monitored via mRFP-EGFP-LC3 tandem reporting, and the functional necessity of autophagy was confirmed using the inhibitor 3-methyladenine (3-MA). dmPGE2 treatment reduced serum transaminases and suppressed hepatic p-JNK activation in APAP-challenged mice. Transcriptomic profiling and qPCR identified Ddit4 as a key responder, which was confirmed in primary hepatocytes. Mechanistically, dmPGE2-induced circLima1 sponges miR-486a/b-3p to upregulate DDIT4, leading to inhibited mTOR phosphorylation and enhanced autophagic flux. AAV-mediated knockdown of circLima1 or Ddit4, as well as pharmacological inhibition of autophagy with 3-MA, abolished the hepatoprotective effects of dmPGE2. dmPGE2 alleviates AILI by activating the circLima1/miR-486/DDIT4 axis to promote protective autophagy. These findings identify the circLima1/DDIT4 pathway as a potential therapeutic target for drug-induced liver injury.
Related Concept Videos
Cirrhosis II: Pathophysiology
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow